27 January 2026   Despite important investment in biomedical research, the most common malignant adult brain tumor - glioblastoma (GBM) - remains largely refractory to existing treatments. Tumors can evade or suppress immunity through a variety of mechanisms, including antigen heterogeneity and  immunosuppressive signaling. Owing in large part to inter-species differences in the immune system and the tumor microenvironment (extracellular matrix composition, stromal cells beha

17 October 2025   Neurodegenerative disorders, such as Alzheimer’s disease  (AD), are highly debilitating, progressive disorders that affect cognitive function and behaviour. Traditionally, biomedical research into AD has relied on animals to model AD pathophysiology and develop treatments. However, none of the treatments tested in AD animal models were able to halt or reverse cognitive decline in AD patients. The failure rate in clinical trials of drugs developed and validat

16 September 2025   Franco-American CRO Genoskin  announces it has raised  $8.7M in its first funding round led by OCCTE (FPCI Occidev Impacts) to grow its human ex vivo skin platform.   In a field that struggles to bridge the gap between preclinical promise and clinical outcome, the project carried by Genoskin has a particular significance. The development of vaccines and therapies for human skin diseases is fraught with difficulties, not least of which is the existence of n

12 June 2025   Cambridge, Massachusetts-based Parallel Bio announces  it has raised $21 million Series A funding to scale up and automate the production of its immune organoid in vitro platform. This funding round led by AIX Ventures was supported by prominent leaders in AI and biotech, including Marc Benioff, founder and CEO of Salesforce.   Beyond infections and autoimmune diseases, it is widely recognized that the human immune systems plays a key role in a great number of

27 October 2025   As we enter a new era of drug discovery, where IND authorization can now be granted based on human data only, marking a clean departure from mandatory animal testing, Qureator's human organ-on-chip platform has laid the groundwork for the world’s first IND approval of its kind .   The IND grant concerns SillaJen's BAL0891-tislelizumab combination therapy to treat solid tumors. Qureator's patient-derived vascularized tumor immune microenvironment (TME) model